Regeneron Pharmaceuticals Newsroom

Regeneron Reports Positive Results for Two Anti-coagulant Drugs

Seeking Alpha02:16

Express News | Regeneron Pharmaceuticals Inc - Regn7508 and Regn9933 Evaluated for Thrombosis Control

BreakingsDec 19 20:00

Regeneron to Advance Two Factor XI Antibodies Into a Broad Phase 3 Program Following Positive Phase 2 Proof-of-concept Results

Regeneron PharmaceuticalsDec 19 13:00

REGN's Eylea HD Shows Non-Inferiority to Eylea in Eye Disease Study

Zacks Dec 18 22:35

Regeneron Pharmaceuticals Shares Are Trading Higher After the Company Announced Its QUASAR Trial Investigating EYLEA HD Met Its Primary Endpoint for the Treatment of Patients With Macular Edema.

BenzingaDec 18 02:16

Regeneron Says Phase 3 Trial of Higher Dose Eye Drug Eylea HD Meets Primary Target

MT NewswiresDec 17 21:01

What 25 Analyst Ratings Have To Say About Regeneron Pharmaceuticals

BenzingaDec 17 21:00 · Ratings

Express News | Bayer AG - Approximately 90% of Aflibercept 8 Mg Patients Were Extended to Every 8-Week Dosing and Maintained Their Interval Through 36 Weeks

BreakingsDec 17 20:01

Express News | Regeneron Pharmaceuticals Inc - Supplementary Biologics License Application Planned for Q1 2025

BreakingsDec 17 20:00

Express News | Regeneron Pharmaceuticals Inc - Safety Data Consistent With Known Eylea Hd and Eylea Profiles

BreakingsDec 17 20:00

Express News | Eylea Hd® (Aflibercept) Injection 8 Mg Phase 3 Trial Meets Primary Endpoint Showing Improved Vision With Extended Dosing Intervals in Patients With Macular Edema Following Retinal Vein Occlusion

BreakingsDec 17 20:00

Is Regeneron Pharmaceuticals, Inc. (REGN) the Best Weight Loss Stock to Buy Now According to Hedge Funds?

Yahoo FinanceDec 17 19:53

Regeneron Pharma Price Target Announced at $165.00/Share by Canaccord Genuity

Dow JonesDec 17 19:31 · Ratings

Regeneron Pharma Initiated at Hold by Canaccord Genuity

Dow JonesDec 17 19:31 · Ratings

EYLEA HD (Aflibercept) Injection 8 Mg Phase 3 Trial Meets Primary Endpoint Showing Improved Vision With Extended Dosing Intervals in Patients With Macular Edema Following Retinal Vein Occlusion

Regeneron PharmaceuticalsDec 17 13:00

Regeneron Announces Presentation at the 43rd Annual J.P. Morgan Healthcare Conference

Regeneron PharmaceuticalsDec 17 13:00

Worst Performing Stocks for Tax Loss Selling – Wolfe

Seeking AlphaDec 17 03:59

Regeneron Named to Dow Jones Sustainability World Index for Sixth Consecutive Year

Regeneron PharmaceuticalsDec 16 13:00

Regeneron Down 15.5% Year to Date: How to Play the Stock?

Zacks Dec 13 21:25

BofA Restarts Coverage of 11 Large-cap Biopharmas

Seeking AlphaDec 11 06:01